Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
Use este enlace para citar
http://hdl.handle.net/2183/23228
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution 4.0 International LIcense (CC-BY 4.0)
Colecciones
- INIBIC-VC - Artigos [37]
Metadatos
Mostrar el registro completo del ítemTítulo
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antiviralsAutor(es)
Fecha
2019-06-03Cita bibliográfica
Rodríguez-Osorio I, Mena A, Meijide H, Morano L, Delgado M, Cid P, Margusino L, Pedreira JD, Castro Á. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One. 2019 Jun 3;14(6):e0217052.
Resumen
[Abstract] BACKGROUND:
Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC).
OBJECTIVE:
To compare the incidence of liver-related events and mortality between patients aged ≥65 and <65 years.
METHODS:
Prospective study comparing patients aged ≥65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups.
RESULTS:
Five hundred patients (120 aged ≥65 and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (P = 0.283) and liver-related mortality (P = 0.254) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and younger groups, respectively (P = 0.747). The diagnosis of HCC was 8 months after the end of treatment.
CONCLUSIONS:
The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged ≥65 years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged ≥65 years.
Descripción
Research article
Versión del editor
Derechos
Creative Commons Attribution 4.0 International LIcense (CC-BY 4.0)
ISSN
1932-6203